Patents Assigned to Chelatexx, LLC
  • Publication number: 20130089603
    Abstract: A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.
    Type: Application
    Filed: July 22, 2010
    Publication date: April 11, 2013
    Applicant: CHELATEXX LLC
    Inventor: Ronald Thompson
  • Patent number: 8110186
    Abstract: A method to effectively treat the adverse events of ingested orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric coated activated charcoal member to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: February 7, 2012
    Assignee: Chelatexx, LLC
    Inventor: Ronald J. Thompson